Woodline Partners LP Verve Therapeutics, Inc. Transaction History

Woodline Partners LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$10.81 - $17.96 $248 - $413	23 Added 0.0%	521,112 $6.92 Million
Q4 2023 Feb 14, 2024	SELL	$8.84 - $18.7 $1,511 - $3,197	-171 Reduced 0.03%	521,089 $7.26 Million
Q3 2023 Nov 14, 2023	BUY	$11.42 - $20.82 $1.45 Million - $2.64 Million	126,839 Added 32.16%	521,260 $6.91 Million
Q2 2023 Aug 14, 2023	BUY	$13.34 - $19.9 $106,119 - $158,304	7,955 Added 2.06%	394,421 $7.4 Million
Q1 2023 May 15, 2023	BUY	$14.3 - $24.01 $145,702 - $244,637	10,189 Added 2.71%	386,466 $5.57 Million
Q4 2022 Feb 14, 2023	BUY	$17.85 - $40.7 $22,883 - $52,177	1,282 Added 0.34%	376,277 $7.28 Million
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $3.52 Million - $9.34 Million	224,995 Added 150.0%	374,995 $12.9 Million
Q1 2022 May 16, 2022	SELL	$20.92 - $39.36 $544,484 - $1.02 Million	-26,027 Reduced 14.79%	150,000 $3.42 Million
Q4 2021 Feb 14, 2022	SELL	$31.94 - $54.82 $845,547 - $1.45 Million	-26,473 Reduced 13.07%	176,027 $6.49 Million
Q3 2021 Nov 15, 2021	SELL	$46.0 - $73.99 $203,366 - $327,109	-4,421 Reduced 2.14%	202,500 $9.52 Million
Q2 2021 Aug 16, 2021	BUY	$31.92 - $60.25 $6.6 Million - $12.5 Million	206,921 New	206,921 $12.5 Million

186

73.3M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $317M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.